Financial Daily from THE HINDU group of publications Wednesday, Mar 08, 2006 |
|
|
|
|
|
|
|
Industry & Economy
-
Pharmaceuticals Pharma cos fight pitched battle on patent turf P.T. Jyothi Datta
Mumbai , March 7 The one-year-old product patent regime in India, it seems, is fighting fit. Torrent has opposed the grant of a patent on Astra Zeneca's cholesterol drug Rosuvastatin, while Ranbaxy has filed for pre-grant opposition against Pfizer's anti-fungal drug Voriconazole. Ajanta Pharma has opposed Eli Lilly's patent application on erectile dysfunction drug Tadalafil, and Cipla and Hetero have opposed Wockhardt's patent application on anti-bacterial drug Nadifloxacin. Meditab Specialities has opposed the grant of a patent to the Gilead-Roche combine on its bird-flu drug Oseltamivir, patent attorneys told Business Line. But this is just a peep into the argumentative world of pre-grants, with drug-makers fighting at least 100-odd such oppositions at patent offices across the country, a legal expert said. A pre-grant opposition allows people to contest a patent application filed by a company at the patent office. After hearing out the patent-holder and the opposition, the patent office eventually grants or rejects the drug firm's application for a patent. Only recently, the Indian Patent office rejected Novartis's claim for a patent on imatinib mesylate, a cancer drug sold by it under the brand name Gleevec. According to a patent lawyer, there are more than 40 pre-grant oppositions in Delhi, over 20 in Chennai, an excess of 15 in Mumbai, and a similar number in Kolkata. In Delhi alone, Ranbaxy has about 12 pre-grant oppositions and Torrent about 15, he added. Ranbaxy is also reported to be opposing Eli Lilly's patent application on Tadalafil and Torrent is opposing Astra Aktiebolag's patent application on a pharmaceutical formulation of ulcer drug Omeprazole, a lawyer said. Mr Ramesh Adige, Executive Director of Ranbaxy, said: "We do not comment on specific issues. However, our intellectual property team makes a careful analysis on a case-to-case basis to examine and assess the use of the provisions available under the Indian Patent Law for pre-grant and post-grant opposition." Admitting that pre-grant oppositions are being actively fought out at different centres, Calcutta-based patent firm S. Majumdar & Co said that it has filed over 40 pre-grant oppositions at patent offices across the country. And Gujarat-based Torrent Pharma accounts for about 50 percent of these opposition cases, according to Mr S. Majumdar, patent attorney.
Related Stories: More Stories on : Pharmaceuticals | IPR
Article E-Mail :: Comment :: Syndication :: Printer Friendly Page
|
Stories in this Section |
|
The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription Group Sites: The Hindu | Business Line | Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |
Copyright © 2006, The
Hindu Business Line. Republication or redissemination of the contents of
this screen are expressly prohibited without the written consent of
The Hindu Business Line
|